Faith Davies, MBBCh, MRCP, MD, FRCPath from UAMS Myeloma Institute, Arkansas, AZ gives an update on the use of trametinib, which is a MEK inhibitor, in multiple myeloma (MM). The response rate was 20% when given as a single agent and around 50% when given in combination with other drugs in patient with a RAS mutation. According to Prof Davies, the question is why the response is not 100% and her group has looked at, for example, clonal heterogeneity and the downstream expression of RAS in attempt to find an answer to this question. There may also be other groups of patients who might respond well to the drug, according to Prof Davies.
Recorded at the Myeloma 2016 meeting held in Boston, MA.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates